Acromegaly It (octreotide acetate) is indicated to reduce blood levels of growth hormone and IGF-I in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I it levels . In patients with acromegaly, Sandostatin reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I to within normal ranges in 50%-60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with it to reduce blood levels of growth hormone and IGF-I offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin; these trials were not optimally designed to detect such effects. Carcinoid Tumors it is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Sandostatin studies were not designed to show an effect on the size, rate of growth, or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas). it is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Sandostatin studies were not designed to show an effect on the size, rate of growth, or development of metastases.
Growth hormone antagonist
Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). It also suppresses LH response to gonadotrophin-releasing hormone and reduces the secretion of gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin and pancreatic polypeptide.
Acromegaly it (octreotide acetate) is indicated to reduce blood levels of growth hormone and IGF-I it in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I it levels . In patients with acromegaly, Sandostatin reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I it to within normal ranges in 50%-60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with Sandostatin to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with Sandostatin; these trials were not optimally designed to detect such effects. Carcinoid Tumors Sandostatin is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Sandostatin studies were not designed to show an effect on the size, rate of growth or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas) Sandostatin is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Sandostatin studies were not designed to show an effect on the size, rate of growth or development of metastases
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine.
Sensitivity to this drug or any of its components.
Local pain, stinging, tingling at site of inj; anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, loose stools, steatorrhoea; biliary tract abnormalities. Hypoglycaemia and hyperglycaemia, hypothyroidism, cardiac conduction abnormalitles, pancreatitis
Pregnancy Category B There are no adequate and well-controlled studies of octreotide use in pregnant women. Reproduction studies have been performed in rats and rabbits at doses up to 16 times the highest recommended human dose based on body surface area and revealed no evidence of harm to the fetus due to octreotide. However, because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. In postmarketing data, a limited number of exposed pregnancies have been reported in patients with acromegaly. Most women were exposed to octreotide during the first trimester of pregnancy at doses ranging from 100-300 mcg/day of Sandostatin s.c. or 20-30 mg/month of Sandostatin, however some women elected to continue octreotide therapy throughout pregnancy. In cases with a known outcome, no congenital malformations were reported. Nursing Mothers It is not known whether octreotide is excreted into human milk. Because many drugs are excreted in human milk, caution should be exercised when octreotide is administered to a nursing woman.
A limited number of accidental overdoses of Sandostatin® in adults have been reported. In
adults, the doses ranged from 2,400–6,000 micrograms/day administered by continuous
infusion (100-250 micrograms/hour) or subcutaneously (1,500 micrograms t.i.d.). Adverse
events in some patients included arrhythmia, hypotension, cardiac arrest, brain hypoxia,
pancreatitis, hepatitis steatosis, hepatomegaly, lactic acidosis, flushing, diarrhea, lethargy,
weakness, and weight loss.
Sandostatin Injection given in intravenous boluses of 1 mg (1000 mcg) to healthy volunteers
did not result in serious ill effects, nor did doses of 30 mg (30,000 mcg) given intravenously
over 20 minutes and of 120 mg (120,000 mcg) given intravenously over 8 hours to research
patients.
Store at 2-8° C. Stable at room temperature for up to 14 days.
.png&w=384&q=75)